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SHORT COMMUNICATION
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The failure of chemotherapeutic agents to be highly effective
against most human cancers is widely attributed to drug
resistance (Curt et al., 1984; Goldie & Coldman, 1985).
Resistance mechanisms are various and may result from
selective pressures acting on a genetically unstable
population. Resistance does not occur in normal renewal
tissues and their sensitivity is dose limiting (Goldie &
Coldman, 1985). It has recently been suggested that it might
be possible to take advantage of the resistance of cancer cells
and the sensitivity of normal cells to anti-cancer drugs
(Bagshawe, 1986). Hydroxyurea (HU) which inhibits DNA
synthesis probably through its action on ribonucleotide
reductase (Ackerblom et al., 1981) is relatively ineffective
against most solid cancers and resistance readily develops
(Ariel, 1970). It was therefore suggested that treatment with
inhibitors of DNA synthesis should cause more marked
inhibition of DNA synthesis in normal renewal tissues than
in resistant cancers. If so, then it might be possible to
incorporate precursors of DNA that are cytotoxic, or
suitable for scintigraphic imaging, selectively into tumour cell
DNA.
It was further suggested (Bagshawe, 1986) that this
approach might be explored using the pyrimidine analogues
5-iodo-2'-deoxyuridine (IUdR) and 5-bromo-2'-deoxyuridine
(BUdR) which differ from thymidine, the normal pyrimidine
base, only by substitution of a halogen for the 5-methyl
group. They compete with thymidine for phosphorylation
and incorporation into DNA (Prusoff, 1959; Djordjevic &
Szybalski, 1960). IUdR is rapidly dehalogenated unless
incorporated into DNA but IUdR in DNA is retained until
the cell divides or dies. IUdR and BUdR are known radio-
and photo-sensitisers (Djordjevic & Szybalski, 1960) and
12I-IUdR is a potent cytotoxic agent (Hofer, 1980).
Preliminary experiments to test the hypothesis were
performed in nu/nu mice carrying a human choriocarcinoma
xenograft (CC3) (Figure 1 a-h). Group 1 (Figure la) received
only 125I-IUdR and tissues excised 24h later showed, as
have previous studies (Shuhmacher et al., 1974; Hampton &
Eidinoff, 1961) that uptake of 125I-IUdR was -4 times
greater in small intestine and colon than in tumour. When
HU was given before 125I-IUdR (group 2, Figure lb) the
total counts for intestinal tissues were substantially reduced
but tumour counts were not reduced, indicating differential
sensitivity to HU and suggesting that DNA synthesis
continued in the tumour when it was suppressed in normal
renewal tissues.
Drugs which block thymidine synthesis increase utilisation
of extracellular thymidine (Tattersall & Harrap, 1973) or
thymidine analogue, probably through the thymidine salvage
pathway (Sneider & Potter, 1969). They may reduce the
thymidine pool (Tattersall & Harrap, 1973; Taylor et al.,
1983) thereby favouring uptake of a thymidine analogue and
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they may delay dehalogenation of IUdR (Prusoff, 1963). 5-
fluoro-2'-deoxyuridine and 5-fluorouracil (5FU) increase
uptake of IUdR by S phase cells probably through a
combination of these mechanisms (Djordjevic & Szybalski,
1960; Benson et al., 1985). We therefore gave 5FU to
tumour bearing mice (group 3, Figure Ic) followed by l25J1
IUdR and found that mean counts in high uptake tissues
(intestine, spleen, bone marrow) increased 3-5 fold compared
with those from mice receiving 1251-IUdR alone. Mean
tumour counts increased almost 7-fold compared with 125b-
IUdR alone.
Methotrexate (MTX), which reduces thymidine synthesis
through its anti-folate action, was also given to CC3 bearing
mice (Figure Id). MTX produced a less marked increase in
uptake of 125I-IUdR than 5FU in the dosages employed, but
tumour uptake was again increased relative to that by
normal tissues. We had therefore shown that a fluoro-
pyrimidine and a folate antagonist increased uptake of 1251_
IUdR in both tumour and normal renewal tissues.
In the next study (group 5, Figure le) 5FU and HU were
given together before and during exposure of the mice to
125I-IUdR. There was a reduction in uptake by all tissues
compared with group 3 (Figure ic) which received only 5FU
and 125I-IUdR but the reduction in tumour uptake was less
marked so that the mean tumour to colon ratio was 0.91. A
similar effect occurred when MTX and HU were given
(group 6, Figure If) but the effect of reducing normal tissue
uptake of 125I-IUdR was greater and the mean
tumour:colon ratio was 4.5.
Since uptake of IUdR is restricted to cells in S phase or
engaged in unscheduled DNA synthesis (Lewensohn et al.,
1982), a high proportion of tumour cells is likely to be
labelled only by repeated administration. This was studied
first by giving HU and '25I-IUdR on each of 3 successive
days (Figure ig). Intestinal tissue counts were not higher
than after the same drugs given once (Figure lb) but counts
in the tumour were increased giving a mean tumour:colon
ratio of 2.4. When 125I-IUdR was given after HU and 5FU
on 3 successive days a mean tumour:colon ratio of 8.1 was
obtained. The proportion of total administered dose retained
in the tumour was 0.7%g-1 24h after the last injection of
125I-IUdR.
These studies achieved a selective uptake of 125I-lUdR in a
human cancer xenograft in mice. Prolonged retention of
125I-IUdR by the tumours was indicated by the data from
groups 7 and 8 (Figure Ig and 1h), and this was consistent
with incorporation of 125I-IUdR into DNA. Excretion of
1251 was not complete by 24h so that free 1251 or 1251
bound non-specifically to protein (Prusoff, 1963) contributed
to both tissue and tumour radioactivity when measured by
gamma counting the digested tissues.
The intracellular location of 125I-IUdR is particularly
relevant to its potential cytotoxicity; within the nucleus it is
highly cytotoxic but toxicity is low when 125I-1UdR is
confined to the cell membrane (Hofer, 1980). Autoradio-
graphs were therefore obtained. Figure 2 shows autoradio-
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Figure 1 Tissue and tumour uptake of 125INUdR. The histograms show tissues in the same order for each study as indicated in
a. Bars indicate 1 s.d. Groups of 4 or 5 nu/nu mice carried xenografts of a human choriocarcinoma (CC3) 0.5-1.5 cm diameter on
one flank. The tumour was obtained at surgery from a patient who had no prior chemotherapy; it has been passaged for 6 years,
secretes human chorionic gonadotrophin and maintains its original morphological and growth rate characteristics. The mice
weighed 20-25g and received standard feed and water ad libitum with added potassium iodide. 1.25pCi 125I-IUdR (5mCigg-1,
Amersham International, UK) was given to each mouse (except group 8 detailed below). Other drugs (see below) were given by
i.p. route 24h before 125I-IUdR and the same dose was repeated at the time of receiving 125I-IUdR. The mice were killed by
cervical dislocation 24h after 125I-IUdR administration, the organs dissected out immediately,. blotted, weighed, digested in 7 M
KOH for 12h and the gamma emission counted.
Mice received the following agents: group 1 (a), saline only; group 2 (b), HU 50mgkg-1; group 3 (c), SFU 20mgkg-1; group 4
(d), MTX 5 mgkg-1; group 5 (e), HU 50 mgkg- 1+SFU 20 mgkg-1; group 6 (f), HU 50 mgkg- I +MTX Smgkg-1; group 7 (g),
as group 2 on 3 successive days; group 8 (h), HU 50mgkg-1+SFU 20mgkg-1+MTX 5mg kg - i.p. 30min before O0pCi 1251-
IUdR i.v.; HU was repeated 1 h and folinic acid given 5 mgkg-
1 2h after IUdR on 3 successive days.
Table I Tumour and tissue nuclear grain counts 24h after 125I-IUdR and tumour/colon ratios by tissue counting and nuclear grain counts
Mean nuclear grain counts/cell by autoradiography
CC3 Tumour
Necrotic Tumourl
Agents used in areas of Colon colon by
addition to Tumour/colon by Tumour cell Non-neoplastic tumour muscularis nuclear
Group 125I-IUdR tissue counting nuclei nuclei 100I m-2 Liver Bone marrow Colon mucosa grain count
1. nil 0.24 3.68 0.27 0.26 0.12 1.54 0.16 2.38
2. HU 0.77 3.84 0.09 0.18 0.12 0.53 0.17 7.24
3. 5FU 0.43 28.06 0.43 0.05 0.36 4.65 0.15 6.03
4. MTX 0.38
5. HU, 5FU 0.91
6. HU, MTX 4.5 14.43 0.06 0.10 0.47 0.45 0.59 0.15 24.4
7. HU (x3) 2.4 6.67 0.05 0.16 0.10 0.49 0.09 13.47
8. HU, 5FU, MTX (x 3) 8.1
9. HU, 5FU(x 5) 24.67 0.05 0.16 0.61 0.94 0.09 26.20
Table I Groups 1-8 are described under Figure 1 and group 9 under Figure 2. The tumour:colon tissue count ratio is derived from the data
shown in Figure 1. Additional mice were included for autoradiography in groups 1, 2, 3, 6, 7; protocols were identical except that they
received a large (lSyCi) dose of 1251-IUdR.
To perform nuclear grain counts the slides of tumour and colon tissue were examined under x 100 oil immersion objective. An eyepiece
graticule comprising 25 points contained within a circle and divided into 4 quadrants (Graticules Ltd., Tonbridge, Kent) was used to select
tumour nuclei for counting. Where a point overlay or touched a nucleus the grains within the nucleus were counted. Where a point did not
fall directly over or touch the edge of a nucleus, the nucleus of the first cell on an imaginary straight line to the left was used. Where this line
crossed the perimeter of the graticule no point counting could be carried out. Different fields were examined until a total of >400 nuclei had
been counted. The number of grains confined within an area bounded by the nuclear membrane were counted. Grains outside the nuclear
membrane were not included. Nuclear grain counts were performed on sections of colon by examining at least 10 crypts cut longitudinally so
that the distribution of grains within crypts could be assessed. Starting at the mid-point of the base of the crypt and ascending on either side
to the tip, nuclear grains were counted. Mean grain densities per nucleus were calculated from at least 400 nuclei.
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Figure 2 Autoradiographs of CC3 tumour (a) and colon (b) from a nu/nu mouse which received 5FU 20mgkg-1 +HU
50mgkg- i.p. followed after 30min by 1251 IUdR 50pCi i.v. on 5 alternate days (group 9, Table I). The mice were killed on day
11. Colon from a mouse which received 5FU and 251IIUdR but no HU (group 3) is shown in (c) for comparison.
Photomicrographs were taken at an original magnification x 240, enlarged x 3.
Pieces of liver, colon and CC3 tumour xenograft were fixed in 10% buffered formalin for 24h. Femoral bone pieces were
decalcified in an EDTA formalin mixture (80gEDTA in 950ml of distilled water plus 50ml formalin) for 16h and then post-fixed
in 10% buffered formalin for 8h. Tissues were processed through a graded alcohol sequence and an inhibisol/chloroform mixture
to paraffin wax. Sections were cut at 4pm and mounted on subbed slides (dipped in 0.5%/ gelatine in 0.05% potassium chromium
sulphate in distilled water). Slides were covered by Kodak ARIO stripping film and autoradiographs were prepared by standard
methods.
graphs of tumour (group 9) and colon (group 9 and group 3
for comparison). The mean nuclear grain count ratio for
tumour:colon was 26.2 in group 9. Compared with total
tissue counts nuclear grain counts consistently suggested a
more favourable distribution of 125I-IUdR (Table I). In the
5 groups studied by both techniques the mean nuclear grain
count ratios were 5.4-14.0-fold higher than the respective
tissue count ratios. Cumulative frequencies of nuclear grain
counts were determined for colon and tumour and these also
confirmed that the number of labelled colonic nuclei and the
number of grains within them were reduced by the addition
of HU to 125I-IUdR but the corresponding numbers in
tumour nuclei were little changed.
Limited studies using cytosine arabinoside (CA) in place
of HU and studies on a human colorectal carcinoma
xenograft have given comparable results to those described
here with the CC3 tumour but with slow growing tumours
125I-IUdR uptake is likely to be lower.
No attempt was made in these early studies to ensure the
CC3 tumour was resistant to HU nor to optimise the
dosage and timing of the drugs used. Nevertheless, the
tumour: normal tissue distribution of 125I-IUdR has been
modified in this xenograft model to one that is potentially
favourable for diagnostic and therapeutic purposes by
blocking normal tissue uptake with HU and, in addition,
giving agents which increase 125I-IUdR uptake by
uninhibited cells. Further enhancement of tumour uptake of
1251-IUdR may be possible by inhibiting thymidine kinase
with 5'-aminothymidine (Fischer et al., 1986). The role of
HU or CA in this approach is a reversal of their normal role
as anti-cancer agents.
Refinement of the present technique might provide a basis
for estimating cell deaths as they occur spontaneously, or as
a result of therapy in animal tumour models and perhaps in
man. Immunoscintigraphic methods are used clinically to
identify sites of drug resistant tumour (Bagshawe, 1985);
131 -IUdR or 1231-IUdR may prove superior to antibody
directed isotopes for some tumours because retention of
radioactivity in blood, liver and lungs is relatively low.
Since IUdR and BUdR are known to act as radio-
sensitisers and photosensitisers their selective uptake by
tumour cells may prove advantageous. Their possible role as
sensitisers to alkylating agents (Prusoff, 1963) or other
chemotherapeutic drugs requires re-investigation. 125I, 1231
and ""Br are characterised by Auger electron emission which
greatly enhances their therapeutic potential (Hofer 1980,
Lemotte & Little, 1984). The penalty for achieving a selective
uptake of a thymidine analogue into tumours is a period
of inhibition of DNA synthesis and consequent cell loss
from normal tissues. The ultimate equation is the
therapeutic:toxicity ratio which reflects total cell losses in
tumour and normal tissues resulting from the drugs used to
achieve the selective distribution of the analogue as well as
the analogue itself.
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